Treatment Options in Refractory Autoimmune Encephalitis.

Area of Science:

• Neuroimmunology
• Immunology
• Neurology

Background:

• Autoimmune encephalitis is an immune-mediated neurological disorder.
• Early immunotherapy is crucial for managing autoimmune encephalitis.
• Refractory cases pose significant clinical challenges with no established guidelines.

Purpose of the Study:

• To review current evidence on treatments for refractory autoimmune encephalitis.
• To identify methodological issues in existing studies.
• To summarize proposed therapies for treatment-resistant autoimmune encephalitis.

Main Methods:

• Systematic review of literature on refractory autoimmune encephalitis treatments.
• Analysis of case reports, case series, and limited controlled studies.
• Evaluation of cytokine-based drugs, plasma cell-depleting agents, and intrathecal therapies.

Main Results:

• First-line treatments include steroids, plasma exchange, and IVIg.
• Second-line options like rituximab and cyclophosphamide are used for unresponsive cases.
• Emerging treatments for refractory cases include targeted immunotherapies with limited evidence.

Conclusions:

• Evidence for advanced therapies in refractory autoimmune encephalitis is largely based on low-level studies.
• Further controlled research is needed to establish efficacy and guidelines for refractory cases.
• Addressing treatment resistance in autoimmune encephalitis remains a critical area for clinical research.